A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia (Certolizumab Pegol)
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Spondylitis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms CRADLE
- Sponsors UCB
Most Recent Events
- 13 Jun 2024 According to UCB media release, data of CHERISH trial having data build on previous pharmacokinetic studies CRIB and CRADLE , will be presented at the European Congress of Rheumatology, EULAR 2024, and provide evidence to inform personalized treatment decisions for patient populations with high unmet need
- 25 Mar 2019 According to a UCB media release, the Health Canada has approved label updates in pregnancy and breastfeeding based on two pivotal pharmacokinetic studies (CRIB and CRADLE).
- 22 Mar 2018 Results published in UCB the Media Release